Treatment of Vulvar Candidiasis
For uncomplicated vulvar candidiasis, use either topical azole antifungals (clotrimazole, miconazole, terconazole) applied intravaginally for 1-7 days OR a single 150-mg oral dose of fluconazole 1.
First-Line Treatment Options
The 2016 IDSA guidelines provide strong recommendations with high-quality evidence for two equally effective approaches:
Topical Intravaginal Azoles
- Clotrimazole 1% cream 5g intravaginally for 7-14 days
- Clotrimazole 2% cream 5g intravaginally for 3 days
- Miconazole 2% cream 5g intravaginally for 7 days
- Miconazole 200 mg suppository for 3 days
- Terconazole 0.4% cream 5g intravaginally for 7 days
- Terconazole 0.8% cream 5g intravaginally for 3 days
- Terconazole 80 mg suppository for 3 days
No single topical agent is superior to another 1. Many of these preparations (clotrimazole, miconazole, butoconazole, tioconazole) are available over-the-counter 2, 3.
Oral Therapy
Fluconazole 150 mg as a single oral dose is equally effective and offers convenience over topical therapy 1, 4.
Severe Acute Vulvovaginitis
For severe disease, use fluconazole 150 mg every 72 hours for 2-3 total doses (strong recommendation; high-quality evidence) 1.
Recurrent Vulvovaginal Candidiasis (RVVC)
For women with 4 or more episodes annually:
- Induction phase: 10-14 days of topical azole OR oral fluconazole
- Maintenance phase: Fluconazole 150 mg weekly for 6 months (strong recommendation; high-quality evidence) 1, 4
This suppressive regimen significantly reduces recurrence rates during the maintenance period.
Azole-Resistant or Non-Albicans Species
For C. glabrata unresponsive to oral azoles:
- First-line: Intravaginal boric acid 600 mg in gelatin capsule daily for 14 days (strong recommendation) 1
- Alternative: Nystatin intravaginal suppositories 100,000 units daily for 14 days 1
- Third option: Topical 17% flucytosine cream ± 3% amphotericin B cream daily for 14 days (weak recommendation) 1
Critical Clinical Pitfalls
Confirm diagnosis before treatment: Symptoms alone are nonspecific. Perform wet mount with 10% KOH to visualize yeast/pseudohyphae and confirm normal vaginal pH (≤4.5) 1. Culture is indicated for recurrent cases or treatment failures to identify non-albicans species.
Avoid treating asymptomatic colonization: 10-20% of women harbor Candida without symptoms—treatment is unnecessary and promotes resistance 2, 5.
Partner treatment is not routinely indicated: VVC is not sexually transmitted. Only treat male partners with symptomatic balanitis using topical antifungals 2, 5.
OTC self-treatment limitations: Reserve for women with previously confirmed VVC experiencing identical symptoms. Any persistence beyond 2 months or treatment failure requires medical evaluation 2, 3.
Special Populations
Pregnancy
Use only topical azoles during pregnancy—7-day regimens are preferred (clotrimazole, miconazole, butoconazole, terconazole) 5, 6. Oral fluconazole is contraindicated due to associations with spontaneous abortion and congenital anomalies 7.
HIV Infection
Treat identically to HIV-negative women, though lower CD4+ counts correlate with increased VVC rates 7. Standard azole regimens remain effective.
Practical Algorithm
- Confirm diagnosis (wet mount + pH)
- Classify severity: Uncomplicated (mild-moderate, sporadic) vs. Complicated (severe, recurrent, non-albicans, immunocompromised host)
- For uncomplicated: Choose fluconazole 150 mg × 1 OR topical azole 1-7 days
- For severe: Fluconazole 150 mg every 72 hours × 2-3 doses
- For recurrent: Induction therapy → fluconazole 150 mg weekly × 6 months
- For treatment failure: Culture for species identification → consider boric acid for C. glabrata
The evidence strongly supports azoles as first-line therapy with 80-90% cure rates 2, 5. Newer agents like ibrexafungerp and oteseconazole show promise for resistant cases but are not yet widely available 7, 8, 9.